No photo of Deborah Toppmeyer

View Scopus Profile

Deborah Toppmeyer

  • 2810 Citations
  • 21 h-Index
1992 …2019
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 15 Similar Profiles
Breast Neoplasms Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Paclitaxel Medicine & Life Sciences
Recurrence Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
9-aminocamptothecin Medicine & Life Sciences
Triple Negative Breast Neoplasms Medicine & Life Sciences
Mutation Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1992 2019

  • 2810 Citations
  • 21 h-Index
  • 44 Article
  • 8 Review article
  • 1 Editorial
  • 1 Letter
1 Citation (Scopus)

A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance)

Rashkin, S. R., Chua, K. C., Ho, C., Mulkey, F., Jiang, C., Mushiroda, T., Kubo, M., Friedman, P. N., Rugo, H. S., McLeod, H. L., Ratain, M. J., Castillos, F., Naughton, M., Overmoyer, B., Toppmeyer, D., Witte, J. S., Owzar, K. & Kroetz, D. L., Mar 1 2019, In : Clinical Pharmacology and Therapeutics. 105, 3, p. 738-745 8 p.

Research output: Contribution to journal › Article

Pharmacogenetics
Disease-Free Survival
Area Under Curve
Genome
Breast Neoplasms

Decisional conflict among breast cancer patients considering contralateral prophylactic mastectomy

Manne, S., Smith, B., Mitarotondo, A., Frederick, S., Toppmeyer, D. & Kirstein, L., May 1 2019, In : Patient Education and Counseling. 102, 5, p. 902-908 7 p.

Research output: Contribution to journal › Article

Breast Neoplasms
Self Efficacy
Motivation
Neoplasms
Foster Home Care
8 Citations (Scopus)

Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study

Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., Hui, R., Curigliano, G., Toppmeyer, D., O'Shaughnessy, J., Loi, S., Paluch-Shimon, S., Tan, A. R., Card, D., Zhao, J., Karantza, V. & 1 othersCortés, J., Mar 1 2019, In : Annals of Oncology. 30, 3, p. 397-404 8 p.

Research output: Contribution to journal › Article

Triple Negative Breast Neoplasms
Therapeutics
Population
Safety
pembrolizumab
7 Citations (Scopus)

Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: Cohort B of the phase II KEYNOTE-086 study

Adams, S., Loi, S., Toppmeyer, D., Cescon, D. W., De Laurentiis, M., Nanda, R., Winer, E. P., Mukai, H., Tamura, K., Armstrong, A., Liu, M. C., Iwata, H., Ryvo, L., Wimberger, P., Rugo, H. S., Tan, A. R., Jia, L., Ding, Y., Karantza, V. & Schmid, P., Mar 1 2019, In : Annals of Oncology. 30, 3, p. 405-411 7 p.

Research output: Contribution to journal › Article

Triple Negative Breast Neoplasms
Therapeutics
Disease-Free Survival
pembrolizumab
Safety
127 Citations (Scopus)

Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer

Sparano, J. A., Gray, R. J., Makower, D. F., Pritchard, K. I., Albain, K. S., Hayes, D. F., Geyer, C. E., Dees, E. C., Goetz, M. P., Olson, J. A., Lively, T., Badve, S. S., Saphner, T. J., Wagner, L. I., Whelan, T. J., Ellis, M. J., Paik, S., Wood, W. C., Ravdin, P. M., Keane, M. M. & 10 othersGomez Moreno, H. L., Reddy, P. S., Goggins, T. F., Mayer, I. A., Brufsky, A. M., Toppmeyer, D., Kaklamani, V. G., Berenberg, J. L., Abrams, J. & Sledge, G. W., Jul 12 2018, In : New England Journal of Medicine. 379, 2, p. 111-121 11 p.

Research output: Contribution to journal › Article

Adjuvant Chemotherapy
Breast Neoplasms
Gene Expression
Recurrence
Drug Therapy